Botox Must Be Excluded From Medicare Price Negotiation, Judge Rules, Citing Ingredient Made From Human Blood Plasma

A federal judge ruled that Botox qualifies for Medicare’s plasma-derived drug exemption, blocking a negotiated price that would have taken effect in 2028 unless the decision is overturned.